在薄膜中"稳定"无形二烯
Chaima Tizaoui1,2,3, Ivo B Rietveld1, Haykel Galai2,3
1Univ. Rouen Normandie, Normandie Univ., SMS, UR 3233, F-76000 Rouen, France.
Langmuir : the ACS journal of surfaces and colloids
|January 3, 2025
概括
无形烯薄膜在干燥条件下表现出稳定性,但在潮湿环境中结晶. 聚乙烯甘醇添加影响结晶,低度和高湿度导致纳米尺寸的晶体.
科学领域:
- 材料科学 材料科学 材料科学
- 制药科学 制药科学
- 物理化学 物理化学
背景情况:
- 无形固体分散对于提高药物的溶解性和生物可用性至关重要.
- 托芬是一种非类固醇抗炎药物,通常需要在其无形形式的稳定.
- 薄膜沉积提供了一种控制药物配方和稳定性的方法.
研究的目的:
- 为了研究无形烯在薄膜中的稳定性.
- 为了评估聚乙烯糖醇 (PEG) 和相对湿度对的无形状态的影响.
- 了解基托在无形薄膜中的结晶行为.
主要方法:
- 使用螺旋涂层制备无形基/PEG薄膜.
- 在不同的相对湿度条件下,薄膜稳定性的表征.
- 使用光谱X射线衍射和原子力显微镜进行分析.
主要成果:
- 在干燥条件下,无形烯薄膜在长达4个月的时间内保持稳定.
- 在暴露于相对湿度>50%的薄膜中观察到烯的结晶.
- 低度的二烯和高湿度导致纳米尺寸的晶体,而PEG的效果取决于度.
结论:
- 薄膜沉积稳定无形基,防止在干燥条件下结晶.
- 湿度是诱导无形烯膜结晶的关键因素.
- 聚乙烯甘醇的存在和度可以调节 ketoprofen 在无形膜中的结晶动力学.
相关概念视频
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
281
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
281
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
173
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
173


